Emergent Biosolutions Inc Asset Resilience Ratio
Emergent Biosolutions Inc asset resilience ratio. Emergent Biosolutions Inc (EBS) has an Asset Resilience Ratio of 15.58% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See EBS defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Emergent Biosolutions Inc (2004–2025)
Asset resilience ratio of Emergent Biosolutions Inc from 2004 to 2025. This chart shows how Emergent Biosolutions Inc's Asset Resilience Ratio has changed over time. Read Emergent Biosolutions Inc (EBS) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Emergent Biosolutions Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see EBS current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $205.40 Million | 15.58% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $205.40 Million | 15.58% |
Asset Resilience Insights
- Good Liquidity Position: Emergent Biosolutions Inc maintains a healthy 15.58% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Emergent Biosolutions Inc Industry Peers by Asset Resilience Ratio
Compare Emergent Biosolutions Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 29.37% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Shenzhen Chipscreen Biosciences Co
SHG:688321 |
Drug Manufacturers - Specialty & Generic | 5.10% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
HPGC Renmintongtai Pharmaceutical Corp
SHG:600829 |
Drug Manufacturers - Specialty & Generic | 0.00% |
Emergent Biosolutions Inc Asset Resilience Ratio by Year (2004–2025)
Emergent Biosolutions Inc asset resilience ratio by year from 2004 to 2025. The table below shows the annual Asset Resilience Ratio data for Emergent Biosolutions Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 15.58% | $205.40 Million | $1.32 Billion | +8.42pp |
| 2024-12-31 | 7.16% | $99.50 Million | $1.39 Billion | +0.57pp |
| 2023-12-31 | 6.59% | $120.20 Million | $1.82 Billion | -13.70pp |
| 2022-12-31 | 20.29% | $642.60 Million | $3.17 Billion | +0.82pp |
| 2021-12-31 | 19.48% | $576.10 Million | $2.96 Billion | -2.07pp |
| 2020-12-31 | 21.55% | $621.30 Million | $2.88 Billion | +14.34pp |
| 2019-12-31 | 7.21% | $167.80 Million | $2.33 Billion | +2.18pp |
| 2018-12-31 | 5.03% | $112.20 Million | $2.23 Billion | -11.72pp |
| 2017-12-31 | 16.76% | $179.34 Million | $1.07 Billion | -11.23pp |
| 2016-12-31 | 27.99% | $271.51 Million | $970.11 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $1.04 Billion | -- |
| 2013-12-31 | 0.00% | $0.00 | $626.63 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $564.23 Million | -- |
| 2011-12-31 | 0.36% | $1.97 Million | $546.86 Million | -0.05pp |
| 2010-12-31 | 0.41% | $2.03 Million | $500.32 Million | +0.34pp |
| 2009-12-31 | 0.06% | $215.00K | $344.69 Million | -1.75pp |
| 2004-12-31 | 1.81% | $1.25 Million | $69.06 Million | -- |
About Emergent Biosolutions Inc
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intrav… Read more